Gilead Sciences Inc. (GILD)
Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation
Gilead's lenacapavir may become a blockbuster HIV prophylactic. Biktarvy maintains a dominant market share in the HIV treatment space, contributing significantly to Gilead's revenue growth. Gilead's oncology segment is expanding, with Trodelvy and Yescarta showing potential for accelerated revenue growth.
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.
Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda
Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral remdesivir to the Rwanda Medical Supply for emergency use in response to the Marburg virus disease outbreak.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.94, denoting a +0.12% change from the preceding trading day.
2 Top Picks With Contrarian Potential as Q4 Looms
Subscribers to Chart of the Week received this commentary on Sunday, September 29.
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.79, denoting a -0.24% change from the preceding trading day.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences stock nears its all-time high: buy or sell?
Gilead Sciences (GILD) stock price has staged a strong comeback this year, helped by strong earnings and a recent $40 million settlement with American authorities. It has risen for two consecutive weeks, reaching a high of $84, its highest point since January and a few points below its all-time high of $89.
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
